MedTrace Logo

Hepatocellular Carcinoma (HCC)_Torisel_

NCT01251458 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2016-09-28

No results posted yet for this study

Summary

This is a phase I/II study to evaluate dose limited toxicity and efficacy of Torisel

Conditions

  • Inoperable HCC

Interventions

DRUG

Torisel

Torisel will be administered intravenously as an IV infusion over a 30-minute period in adult clinical studies.

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Winnie Yeo, MD, FRCP · Department of Clinical Oncology, The Chinese University of Hong Kong

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01251458 on ClinicalTrials.gov